Pasar al contenido principal

IDENTIFICACION DE NUEVAS OPORTUNIDADES TERAPEUTICAS EN LA RUTA DE RESPUESTA AL DAÑO EN EL ADN PARA TRATAR CANCER

PID2020-119329RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors

  • Pladevall-Morera, David
  • Castejón-Griñán, María
  • Aguilera, Paula
  • Gaardahl, Karina
  • Ingham, Andreas
  • Brosnan-Cashman, Jacqueline A.
  • Meeker, Alan K.
  • López-Contreras, Andrés J.
High-grade glioma, including anaplastic astrocytoma and glioblastoma (GBM) patients, have a poor prognosis due to the lack of effective treatments. Therefore, the development of new therapeutic strategies to treat these gliomas is urgently required. Given that high-grade gliomas frequently harbor mutations in the SNF2 family chromatin remodeler ATRX, we performed a screen to identify FDA-approved drugs that are toxic to ATRX-deficient cells. Our findings reveal that multi-targeted receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors cause higher cellular toxicity in high-grade glioma ATRX-deficient cells. Furthermore, we demonstrate that a combinatorial treatment of RTKi with temozolomide (TMZ)–the current stand-ard of care treatment for GBM patients–causes pronounced toxicity in ATRX-deficient high-grade glioma cells. Our findings suggest that combinatorial treatments with TMZ and RTKi may increase the therapeutic window of opportunity in patients who suffer high-grade gliomas with ATRX mu-tations. Thus, we recommend incorporating the ATRX status into the analyses of clinical trials with RTKi and PDGFRi., This work was supported by grants from Danish National Research Foundation (DNRF115), Danish Cancer Society (KBVU-2017_R167-A11063), European Research Council (ERC-2015-STG- 679068), Nordea-fonden (02-2017-1749) and the Spanish Ministry of Science and Innovation (PID2020- 119329RB-I00). David Pladevall-Morera was supported with a PhD scholarship from the Lundbeck Foundation (R218-2016-415) and funding from Dansk Kræftforskningsfond. María Castejón-Griñán holds an Incorporación fellowship from the Junta de Andalucía. Paula Aguilera was supported with a Juan de la Cierva formación fellowship from the MICINN and an Incorporación fellowship from the Junta de Andalucía. Toyota Fonden and Læge Sofus Carl Emil Friis og hustru Olga Doris Fonden funded the acquisition of the high-content microscope used in this study.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ATRX, a guardian of chromatin

  • Aguilera, Paula
  • López-Contreras, Andrés J.
ATRX (alpha-thalassemia mental retardation X-linked) is one of the most frequently mutated tumor suppressor genes in human cancers, especially in glioma, and recent findings indicate roles for ATRX in key molecular pathways, such as the regulation of chromatin state, gene expression, and DNA damage repair, placing ATRX as a central player in the maintenance of genome stability and function. This has led to new perspectives about the functional role of ATRX and its relationship with cancer. Here, we provide an overview of ATRX interactions and molecular functions and discuss the consequences of its impairment, including alternative lengthening of telomeres and therapeutic vulnerabilities that may be exploited in cancer cells., We thank Julien Duxin, Hocine Mankouri, Lucía Simón-Carrasco, and María Castejón-Griñán for advice and critical reading of the manuscript. A.L.-C.’s group was funded by grants from the European Research Council (ERC-2015-STG-679068), the Spanish Ministry of Science and Innovation (PID2020-119329RB-I00), and the Junta de Andalucía (PY20_00755, PAIDI2020). P.A. was supported by a postdoctoral fellowship from the Junta de Andalucía and the European Social Fund (202099908313486)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PICH deficiency limits the progression of MYC-induced B-cell lymphoma

  • Castejón-Griñán, María
  • Albers, Eliene
  • Simón-Carrasco, Lucía
  • Aguilera, Paula
  • Sbroggio, Mauro
  • Pladevall-Morera, David
  • Ingham, Andreas
  • Lim, Ernest
  • Guillen-Benitez, Alba
  • Pietrini, Elena
  • Lisby, Michael
  • Hickson, Ian D.
  • López-Contreras, Andrés J.
Plk1-interacting checkpoint helicase (PICH) is a DNA translocase involved in resolving ultrafine anaphase DNA bridges and, therefore, is important to safeguard chromosome segregation and stability. PICH is overexpressed in various human cancers, particularly in lymphomas such as Burkitt lymphoma, which is caused by MYC translocations. To investigate the relevance of PICH in cancer development and progression, we have combined novel PICH-deficient mouse models with the Eμ-Myc transgenic mouse model, which recapitulates B-cell lymphoma development. We have observed that PICH deficiency delays the onset of MYC-induced lymphomas in Pich heterozygous females. Moreover, using a Pich conditional knockout mouse model, we have found that Pich deletion in adult mice improves the survival of Eμ-Myc transgenic mice. Notably, we show that Pich deletion in healthy adult mice is well tolerated, supporting PICH as a suitable target for anticancer therapies. Finally, we have corroborated these findings in two human Burkitt lymphoma cell lines and we have found that the death of cancer cells was accompanied by chromosomal instability. Based on these findings, we propose PICH as a potential therapeutic target for Burkitt lymphoma and for other cancers where PICH is overexpressed., This work was supported by grants from Danish National Research Foundation (DNRF115), European Research Council (ERC-2015-STG-679068), the Spanish Ministry of Science and Innovation-Agencia Estatal de Investigacion (PID2020-119329RB-I00), the Novo Nordisk Foundation (NNF19OC0055203), and the Junta de Andalucía (P20_00755, PAIDI2020). M.C.-G. was supported with a postdoctoral fellowship from the Junta de Andalucía and the European Social Fund (202099908313734) and with a postdoctoral “Juan de la Cierva” fellowship from the MICINN (FJC2020-045915-I). D.P.-M. was supported with a PhD scholarship from the Lundbeck Foundation (R218-2016-415). L.S.-C. was supported with a Postdoctoral Research Contract from the AECC Scientific Foundation (Grant Number POSTD211274SIMÓ). P.A. was supported with a postdoctoral fellowship from the Junta de Andalucía and the European Social Fund (202099908313486). A.G. is funded with a PhD fellowship from the Junta de Andalucía. E.P. is supported by the HORIZON-MSCA ITN RepliFate (101072903). We thank Prof. Fernandez-Capetillo for kindly providing human lymphoma cell lines. We thank Patricia González from the CNIO Histopathology Core Unit, Irene Delgado, and Alexandra Avram for technical support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrated analysis of FHIT gene alterations in cancer

  • Simón-Carrasco, Lucía
  • Pietrini, Elena
  • López-Contreras, Andrés J.
The Fragile Histidine Triad Diadenosine Triphosphatase (FHIT) gene is located in the Common Fragile Site FRA3B and encodes an enzyme that hydrolyzes the dinucleotide Ap3A. Although FHIT loss is one of the most frequent copy number alterations in cancer, its relevance for cancer initiation and progression remains unclear. FHIT is frequently lost in cancers from the digestive tract, which is compatible with being a cancer driver event in these tissues. However, FHIT loss could also be a passenger event due to the inherent fragility of the FRA3B locus. Moreover, the physiological relevance of FHIT enzymatic activity and the levels of Ap3A is largely unclear. We have conducted here a systematic pan-cancer analysis of FHIT status in connection with other mutations and phenotypic alterations, and we have critically discussed our findings in connection with the literature to provide an overall view of FHIT implications in cancer., This study was supported by grants from the EuropeanResearch Council [ERC-2015-STG-679068], the SpanishMinistry of Science and Innovation [PID2020-119329RB-I00], and the Junta de Andalucía [P20_00755, PAIDI2020].Lucia Simon-Carrasco was supported with a PostdoctoralResearch Contract from the Scientific Foundation of theSpanish Association Against Cancer [Grant NumberPOSTD211274SIMÓ]. Elena Pietrini is supported by theHORIZON-MSCA ITN RepliFate [101072903], Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Loss of SLX4IP leads to common fragile site instability and compromises DNA interstrand crosslink repair in vivo

  • Ingham, Andreas
  • Ramaswami, Mukundhan
  • Ramangoudr-Bhojappa, Ramanagouda
  • Pladevall-Morera, David
  • De Santis, Flavia
  • Terriente, Javier
  • Muñoz, Ivan M.
  • Rouse, John
  • Chandrasekharappa, Settara C.
  • López-Contreras, Andrés J.
Common fragile sites (CFSs) are chromosomal loci with inherent characteristics that make them difficult to fully replicate thus rendering them vulnerable to replication stress (RS). Under-replicated CFSs manifest as cytogenetic gaps and breaks on metaphase chromosomes. Moreover, CFSs are hotspots for tumorigenic chromosomal rearrangements. The Fanconi anemia (FA) pathway is at the core of a network of proteins that work to safeguard CFSs during replication and RS. Here, we uncover a novel role of SLX4IP in maintaining CFS stability. We show that SLX4IP localizes stressed CFSs and that its loss exacerbates genome instability, including CFS expression. Furthermore, direct SLX4IP depletion leads to impaired replication and growth deficiencies. SLX4IP and FANCP/SLX4 are epistatic, suggesting that SLX4IP acts with SLX4 to maintain CFS stability. Finally, zebrafish larvae with homozygous knockout of the slx4ip gene showed higher frequency of embryonic anomalies and sensitivity to DNA crosslinking agents, a typical cellular characteristic of patients with FA. Our results establish a causal link between SLX4IP deficiency and chromosomal instability, which may explain how SLX4IP dysregulation contributes to cancer development., This work was funded by grants from Danish Research Foundation (DNRF115), European Research Council (ERC-2015-STG-679068), and the Spanish Ministry of Science and Innovation (PID2020-119329RB-I00). A.I. was supported by a Novo Nordisk Scholarship grant. All experiments presented in this study strictly adhere to Danish ethical guidelines of biological research. M.R, R.R-B, and S.C.C. acknowledge the support from the Intramural research program of the National Human Genome Research Institute, National Institutes of Health., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Circadian regulation of homologous recombination by cryptochrome1-mediated dampening of DNA end resection

  • Romero-Franco, Amador
  • Checa-Rodríguez, Cintia
  • Jimeno, Sonia
  • Castellano-Pozo, Maikel
  • Aguilera, Paula
  • Miras, Héctor
  • Wals-Zurita, Amadeo
  • Jimeno-González, Silvia
  • López-Contreras, Andrés J.
  • Huertas, Pablo
[Data availability] All relevant data are included in the manuscript.Source data are provided with this paper. ChIP-seq data are deposited at GEO under the accession number GSE261427. All data is available from the authors upon request. Source data are provided with this paper., Genomic stability maintenance requires the repair of DNA breaks in the most accurate fashion. So, an exquisite regulatory network controls the choice between different repair mechanisms to maximize genome integrity. This relies mostly at the level of DNA end resection, the initial steps of the homologous recombination. On the other hand, numerous cellular activities follow a 24 h oscillation known as the circadian cycle. Thus, we explored the regulation of the choice between different DNA break repair pathways along the circadian cycle. Here we show that in human cells DNA resection shows a circadian oscillation, with a peak at early morning followed by a partial and progressive reduction until late afternoon. Such regulation depends on the circadian clock core component CRY1, which modulates the anti-resection activity of CCAR2 to limit CtIP at nightfall. Additionally, such regulation requires DNA-PK-mediated phosphorylation of CRY1. Finally, this circadian regulation impacts cancer progression and response to radiation therapy of specific tumours., This work was funded by the R + D + I grants PID2019-104195G and PID2022-136791NB-I00 funded by MICIU/AEI/10.13039/501100011033/ FEDER/UE, the grant P18-RT-1204 from the Consejería de Transformación Económica, Industria, Conocimiento y Universidades, Junta de Andalucía and the grant PRYGN246626HUER from the Asociación Española Contra el Cáncer. The mouse work in the ALC laboratory was funded by the R+D+I grant PID2020-119329RB-I00, the SJ lab is funded by the grant PID2022-140603NB-I00, and the SJG lab is funded by the grant PID2022-139253N, all three funded by MICIU/AEI/10.13039/501100011033/ FEDER/UE. MC-P is the recipient of an MSCA-IF-2020 (coDNAres) that covers his salary and part of the reagents. AR-F is funded with a FPU fellowship from the Spanish Ministry of Education and PA was supported by a postdoctoral fellowship from the Junta de Andalucía and the European Social Fund (202099908313486), and by a postdoctoral grant from the Scientific Foundation of the Spanish Association Against Cancer (POSTD234422AGUI). CABIMER is supported by the regional government of Andalucía (Junta de Andalucía). We thank José Carlos Reyes-Rosa for the critical reading of the manuscript. We also want to thank the Microscopy and Genomic Unit of CABIMER for their support in the experiments., Peer reviewed